SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RO.SW, ROG.SW) reported that, in the first nine months of 2026, Roche sales were up 6% at CER, or up 1% when reported in Swiss francs, to 46.5 billion francs due to strong demand for pharmaceutical products and diagnostic solutions. Sales in the Pharmaceuticals Division was up 7% at CER, or up 2% when reported in Swiss francs, to 36.2 billion francs. The top five growth drivers - Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo - achieved total sales of 16.8 billion francs, an increase of 12% at CER, or up 6% in Swiss francs, compared to the first nine months of 2025.
Roche CEO Thomas Schinecker: 'In the third quarter, we delivered strong sales growth of 7% at constant exchange rates and an increase of 8% in Swiss francs. We confirm our full-year outlook.'
Roche expects an increase in Group sales in the mid single digit range for 2026. Core earnings per share are targeted to develop in the high single digit range. Roche expects to further increase its dividend in Swiss francs.
At prior close on SIX Swiss Exchange, Roche shares were trading at 392.00 Swiss francs.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
